Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy-Reference-Cited by-同舟云学术

Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy

Published:2006-09 Issue:3 Volume:8 Page:E552-E563
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Agoram Balaji,Heatherington Anne C.,Gastonguay Marc R.

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1208/aapsj080364.pdf

Reference49 articles.

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment.J Natl Cancer Inst. 1999;91:1616–1634.

2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med. 2002;346:92–98.

3. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.J Clin Oncol. 2001;19:2865–2874.

4. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.J Natl Cancer Inst. 2002;94:1211–1220.

5. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.Exp Hematol. 2003;31:290–299.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and Pharmacodynamics of Therapeutic Proteins and Nucleic Acids;Pharmaceutical Biotechnology;2024

2. Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients;Clinical Pharmacology in Drug Development;2022-08-31

3. Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors;The Journal of Clinical Pharmacology;2020-10-11

4. Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder;The Journal of Clinical Pharmacology;2020-07-14

5. Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins;Pharmaceutical Biotechnology;2019